Mass Spectrometry

Bruker Mass Spectrometry

Structural O-Glycoform Analysis of SARS-CoV-2 Enabled by Top-down Mass Spectrometry and Trapped Ion Mobility presented by David Roberts, Chemistry Ph.D. Student, Ying Ge Lab and Song Jin Lab, University of Wisconsin-Madison, WI, USA

David Roberts, Chemistry Ph.D. Student, Ying Ge Lab and Song Jin Lab, University of Wisconsin-Madison, on Deciphering the code of complex glycoproteins: extreme resolution and trapped ion mobility detail spike protein glycosylation

Shimadzu Analytical & Measuring

Shimadzu’s Ultra Fast Mass Spectrometry (UFMS) technology is focused on improving three main instrument attributes—acquisition speed, sensitivity and robust operation. UFMS reduces the waiting time during analysis and also reduces the time wasted on instrument maintenance between testing runs so that our triple quad instruments can dramatically improve productivity for labs.

UFMS: An Innovative Approach to Mass Spectrometry

swfcfoster

How to setup your GSD 350 OmniStar/ThermoStar Mass Spec System

Pfeiffer Vacuum GSD 350 Setup

Glycosylation is seen as playing a key role in tumor development.   Researchers at the Bruker-MUSC Clinical Glycomics Center of Excellence are developing and applying new technologies to map glycans in tissue and classify changes that occur during development of cancer.  Glycans present on each glycoprotein in the tissue are analyzed using MALDI Imaging mass spectrometry, a label-free molecular imaging technique, to correlate specific glycan distributions with disease.  Currently used only for research purposes, if brought to market, these tools promise earlier cancer detection and customized therapies.  Learn more by watching this presentation by Dr. Richard Drake.

Agents of Change: Tracking Tumor Progression With MALDI Imaging of Glycans

Oncotarget

Oncotarget Volume 11, Issue 8 reported Independent validation cohorts of 599 cases of early-stage CRC and 91 cases of late-stage CRC were examined.

Multivariate and univariate survival analyses revealed that high expression of P4HA1 protein was an independent poor prognostic marker for patients with early-stage CRC, especially of the microsatellite stable subtype.

Dr. Michael H. Roehrl from the Department of Pathology, Memorial Sloan Kettering Cancer Center as well as the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center said, "Colorectal cancer (CRC) is one of the most prevalent malignant tumors and the third leading cause of cancer deaths worldwide."

However, molecular biomarkers with more precise prognostic value, preferably with an underlying functional pathophysiologic rationale, are needed, as such markers would enable the scientists to better stratify risk of recurrence in resected early-stage CRC after resection and more accurately select patients for adjuvant therapy, while avoiding overtreatment in low-risk early-stage CRC.

Proteomics with latest-generation liquid chromatography-mass spectrometry can detect 5,000 - 10,000 proteins in one shotgun sequencing event, and such powerful and sensitive technology may enable the researchers to discover prognostic protein biomarkers for early-stage CRC that previous genomic and transcriptomic analyses would have missed.

Combining results from 712 patients, their study shows that collagen prolyl 4-hydroxylase alpha 1 protein expression robustly risk-stratifies early-stage CRC.

The discovery of P4HA1 outcome stratification in early-stage CRC and, in particular, its MSS subtype, may provide an avenue for early-stage CRC risk prognosis and thus improve cancer treatment outcomes by tailoring follow-up frequency and adjuvant therapy intensity.

The Roehrl Research Team concluded, in their Oncotarget Research Paper, that early-stage CRC presents frequent challenges in clinical patient management in that it is currently impossible to predict which patients will have aggressive disease and thus benefit the most from intensive adjuvant chemotherapy vs. those patients who will have less aggressive disease and benefit from surgery alone.

DOI - https://doi.org/10.18632/oncotarget.27491

Full text - https://www.oncotarget.com/article/27491/text/

Correspondence to - Michael H. Roehrl - roehrlm@mskcc.org

Keywords - P4HA1, colorectal cancer, biomarker, prognosis, pathology

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetj...
YouTube - https://www.youtube.com/c/OncotargetY...
LinkedIn - https://www.linkedin.com/company/onco...
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Author Testimonial: Dr. Roehrl - Memorial Sloan Kettering Cancer Center

Author Insight: Prolyl 4-hydroxylase Alpha 1 Protein and Early Stage Colorectal Cancer

Teach Me in 10

What is a cannabis testing laboratory? What kind of testing services do labs provide? What equipment is found in a cannabis testing lab? All of these questions  (and more!) are addressed in this Analytical Cannabis special episode of Teach Me in 10, where we're joined by Jini Curry, cannabis laboratory director.

What is a Cannabis Testing Lab? With Jini Curry

Sekisui XenoTech

Presenter: Maciej Czerwinski, Ph.D., SEKISUI XenoTech Director of Scientific Consulting

Abstract:
The importance of glucuronidation for metabolism of xenobiotics in humans is illustrated by the abundance and broad tissue distribution of the enzymes, the diversity of substrates and reactions catalyzed, as well as a number of distinctive UGT enzymes and their genetic polymorphisms. The involvement of UGTs in metabolism of new drug candidates will be presented as it underscores the enzymes’ importance from regulatory and safety perspectives.

Basic biochemical characteristics of UGTs will be reviewed and examples of major forms of glucuronides formed in humans will be presented. Distinctive properties of acyl-glucuronides and their significance for drug-drug interactions will be highlighted. Factors contributing to underprediction of UGTs’ in vivo contributions to the metabolism of xenobiotics will also be covered. Laboratory approaches aimed at improving these predictions will be covered, as well.

Key concepts discussed in this webinar will include:
 - Significance of UGT-mediated metabolism in drug development process
 - Consequences of formation of acyl-glucuronides
 - Underprediction of in vivo UGT-mediated metabolism

Request a copy of the slides: https://www.xenotech.com/about/events/webinar-role-of-udp-glucuronosyltransferases-in-drug-metabolism-and-drug-drug-interactions/
Questions, comments and requests: https://www.xenotech.com/contact/
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenter:
Dr. Maciej Czerwinski serves as a Director in the Scientific Consulting department at SEKISUI XenoTech. He received his Ph.D. from the University of Maryland at Baltimore Medical School in the Department of Pathology. Dr. Czerwinksi conducted his doctoral thesis research in the Laboratory of Dr. Frank Gonzalez at the National Cancer Institute in Bethesda, followed by a post-doc at the Department of Pharmaceutics, the University of Washington in Seattle. He has been with SEKISUI XenoTech since 1999 and guides the development of products and services for the in vitro analysis of drug safety. Dr. Czerwinski designed a patented method to analyze the in vitro cytokine-mediated drug-drug interactions between biologics and small molecule drugs, and he is also the inventor of SEKISUI XenoTech’s CryostaX single-freeze pooled hepatocytes.

The Important Role of UDP Glucuronosyltransferases in Drug Metabolism and Drug Drug Interactions

Chromatography & Mass Spectrometry Solutions

Experience the future of single-cell sensitivity today. 

Single-cell sensitivity empowers the next generation, helps you explore new applications, reveal cellular diversity and discover new biological insights.

Mass Spectrometry

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.